- NanoVibronix (NAOV, Financial) launches ENvue Drive, the first intelligent robotic platform for bedside feeding tube and vascular line navigation.
- The ENvue Drive platform targets a $10 billion+ market opportunity by enhancing procedural efficiency with AI-powered clinical robotics.
- Development includes automated alignment and positional stability, leveraging existing FDA-cleared electromagnetic guidance technology.
NanoVibronix, Inc. (NAOV), a leader in medical technology innovation, has officially launched an initiative to develop ENvue Driveâ„¢, an advanced robotic platform designed to revolutionize bedside feeding tube and vascular line navigation. The new platform, under the development of the company's ENvue Medical division, aims to automate electromagnetic navigation, thereby increasing procedural efficiency with fewer clinicians present.
Dr. Doron Besser, CEO of NanoVibronix, highlighted that ENvue Drive will integrate intelligent robotics into clinical workflows to address significant unmet needs in the healthcare system, especially under conditions of workforce shortages and increased procedural complexity. According to Dr. Besser, "ENvue Drive aims to empower clinicians by maintaining precision and safety while increasing confidence and consistency in care."
The global enteral feeding device market is projected to reach $3.99 billion by 2030, driven by an aging population and rising chronic illnesses. Similarly, the vascular access device market, which includes PICC lines, is forecasted to exceed $10.5 billion by 2030. This places ENvue Drive at the forefront of a significant market opportunity.
ENvue Drive is intended not to replace clinicians but to support them, especially in critical care settings. It will feature real-time, stabilized positioning and automated bedside alignment, reducing the need for multiple clinicians during procedures. The robotic platform is currently in preclinical development, with engineering prototypes underway and input from clinical advisors being integrated into the design.
Although the ENvue Drive system has not yet been submitted to the FDA, NanoVibronix plans to commence regulatory planning and submission milestones later this year, with a functional prototype expected by the end of the year. This development follows successful strategic moves, including a dual-system acquisition agreement with a major U.S. hospital and the issuance of a new U.S. patent for pediatric feeding tube guidance. As NanoVibronix continues to expand its market presence, it remains committed to advancing standards in non-invasive therapy and clinical navigation.
